D-PATH STUDY NEWSLETTER

SEPTEMBER 2026



STUDY UPDATE

We hope you had an enjoyable summer, and we look forward to a renewed commitment to D-PATH with you in the fall!

As of mid-September, there are 38 pharmacies enrolled in D-PATH, and 104 patients. This represents 17% of our overall target of 600 participants.

Every enrollment matters. Thank you for helping us build momentum and demonstrate the impact of pharmacist-led diabetes care.

COMPLETED PATIENTS

We're excited to share that our first sites now have participants who have completed the full six-month study period!

Site remuneration will be issued quarterly at a rate of $150 for each Intervention participant and $50 for each Usual Care participant who completes the study. We will contact eligible sites at the beginning of October to arrange the next round of payments.

BIG NEWS!!

Crossover from Usual Care to Intervention

The crossover function from Usual Care to Intervention has now been added to the D-PATH algorithm! Once a participant completes the study in the Usual Care group, they may be offered the opportunity to receive Intervention care. Data collected after crossover will not be included in the study analysis, and no additional site remuneration will be provided. However, the participant's algorithm will remain open, allowing you to use it as a tool to guide their ongoing care.

Automatic crossover invitations

Each morning, the system will identify eligible participants who have completed Usual Care and automatically email them an invitation to cross over to Intervention care.

- If the participant accepts, the pharmacy will receive an email asking the team to schedule a new visit.
- If the participant declines, the pharmacy will not receive an email notification.

Sending a crossover invitation manually

You may also send a crossover request manually—for example, if the participant does not receive the automated email.

1. Select Admin from the menu on the left-hand side of your dashboard.
2. Select Crossover Request.
3. Click Send beside the name of the participant you wish to invite.
4. The participant's email address and phone number will populate automatically but can be changed if needed.
5. Select Send Email or Send SMS to send the participant a link to the crossover request.

For manually sent requests, the pharmacy will receive an email notifying you whether the participant accepted or declined the invitation.

STUDENT SUPPORTS AVAILABLE!

Our research students are available for in-person visits to help support you with case-finding and reach out to potential study participants. Please contact us if you would like to have the students visit your site and we will have them reach out to you to set up a day and time that is convenient for you.

Email: dpathstudy@gmail.com
Phone: 825-735-9744

A Clear Path
TO DIABETES CONTROL

BIG NEWS - AGAIN!!

Questionnaires can now be sent to participants electronically!

The following questionnaires are available:

- Intake (Week 0): Patient Questionnaire and DTSQs
- Week 24: Socioeconomic Update, DTSQs, DTSQc, and SDM-Q-9

These questionnaires apply to participants in both the Intervention and Usual Care groups. *Important: The Intake questionnaires must be completed by the end of the Initial Visit (Week 0). The participant's first follow-up visit [Week 6 for the Intervention group or Week 12 for the Usual Care group] cannot be started until the Patient Questionnaire and DTSQs have been completed.*

Sending questionnaires through a study visit

When prompted by the algorithm:

- During the Intake visit, select Send Patient Questionnaire and DTSQs Electronically.
- During the Week 24 visit, select Send Week 24 Survey Electronically.

Sending questionnaires manually

Questionnaires can also be sent manually:

1. Select Admin from the menu on the left-hand side of your dashboard.
2. Select Patient Dashboard.
3. Click Send Survey beside the participant's name.
4. The participant's email address and phone number will populate automatically but can be changed if needed.
5. Select Send Email or Send SMS to send the questionnaire link.

As the participant completes each questionnaire, its status will turn green on the dashboard.

STUDY REMINDERS

Have you ever finished a patient encounter and later realized the patient may have been a good fit for D-PATH? Post this simple two-line script beside your computer or till as a reminder:

"Would you be interested in a pharmacist-led care program designed to help you better manage your diabetes and reduce your risk of diabetes-related complications?"

A Clear Path
TO DIABETES CONTROL

CASE FINDING IDEAS

Review your patient profiles for people who are:

- **Taking metformin alone** and may benefit from adding an agent with cardiovascular and/or kidney benefits.
- **Taking a sulfonylurea**, such as gliclazide or glyburide, and may benefit from a newer medication with a lower risk of hypoglycemia and weight gain, as well as potential cardiovascular and kidney benefits.
- **Taking a lower dose of an SGLT2 inhibitor**, such as empagliflozin 10 mg or dapagliflozin 5 mg, and may be eligible for dose optimization.
- **Taking a DPP-4 inhibitor**, such as sitagliptin, saxagliptin, or linagliptin, and may benefit from switching to a GLP-1 receptor agonist.
- **Taking a low dose of a GLP-1 receptor agonist** and may benefit from further dose titration.

These medication profiles can help identify potential D-PATH participants whose diabetes therapy may benefit from reassessment and optimization.

ETHNICITY INFORMATION REQUIRING VERIFICATION

Due to an IT data-entry issue, the ethnicity recorded at Intake was not saved for several participants. We would appreciate your help verifying this information for the affected participants identified in our emails dated August 1 and August 26.

Accurate ethnicity data are important for describing the study population and conducting any analyses involving participant ethnicity.

Please verify each participant's ethnicity using either:

- The original paper Intake form; or
- Confirmation directly from the participant.

Once verified, please send the information to our team, and we will enter it into the algorithm for you. Thank you to the sites that have already completed this step. If you are unsure which participants at your site require verification, please contact us and we will be happy to clarify.

A Clear Path
TO DIABETES CONTROL